SCHEMBL1471759

SCHEMBL1471759

Cc1ccc(NC(=O)CCc2ccccc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.77
HTT P42858 1/20 0.77
RAB9A P51151 3/20 0.70
LMNA P02545 1/20 0.67
GAA P10253 2/20 0.66
HDAC3 O15379 2/20 0.64
HDAC4 P56524 2/20 0.64
HDAC1 Q13547 2/20 0.64
HDAC7 Q8WUI4 2/20 0.64
HDAC2 Q92769 2/20 0.64
HDAC10 Q969S8 2/20 0.64
HDAC11 Q96DB2 2/20 0.64
HDAC8 Q9BY41 2/20 0.64
HDAC6 Q9UBN7 2/20 0.64
HDAC9 Q9UKV0 2/20 0.64
HDAC5 Q9UQL6 2/20 0.64
TSHR P16473 1/20 0.64
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13389060 0.93 MAPT (0.77) MAPTHTTRAB9ALMNAGAA
SCHEMBL4401159 0.90 TRPV1 (0.75) MAPTHTTRAB9AHDAC3HDAC4
Methyl Alcohol SCHEMBL4593446 0.88 MAPT (0.93) MAPTHTTRAB9ALMNAGAA
SCHEMBL3061430 0.88 MAPT (1.00) MAPTHTTRAB9ALMNAGAA
Hydrochloric Acid SCHEMBL27689202 0.86 MAPT (0.96) MAPTHTTRAB9ALMNAGAA
SCHEMBL10954256 0.86 MEN1 (0.59) MAPTHTTRAB9AGAAHDAC3
SCHEMBL13776958 0.85 HDAC2 (0.59) MAPTHTTRAB9AGAAHDAC3
SCHEMBL14096326 0.85 ALDH1A1 (0.74) MAPTHTTRAB9ALMNAGAA
SCHEMBL11705109 0.85 TRPV1 (0.82) MAPTHTTRAB9ALMNAGAA
SCHEMBL13356363 0.85 MAPT (0.80) MAPTHTTRAB9ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119998260-A Process for preparing amides from esters 巴斯夫欧洲公司 2025-05-13 CN disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
CN-109796423-B Method for synthesizing 1, 3-thiazine-4-ketone under metal-free catalysis condition 温州大学 2022-11-11 CN disclosed
CN-111217694-B Method for selectively reducing carbon-carbon double bond in alpha, beta-unsaturated carbonyl compound 五邑大学 2022-09-30 CN disclosed
CN-111217694-A method for selectively reducing carbon-carbon double bond in α, beta-unsaturated carbonyl compound 五邑大学 2020-06-02 CN disclosed
WO-2020015698-A1 METHOD FOR PREPARING COAGULATION FACTOR XIA INHIBITOR AND INTERMEDIATE THEREOF 江苏恒瑞医药股份有限公司 2020-01-23 WO disclosed
US-20170202795-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H LEE MOFFITT CANCER CT & RES (US) 2017-07-20 US disclosed
US-20160326125-A1 SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-10 US disclosed
EP-1898910-B1 QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA NV (BE) 2016-09-28 EP disclosed
EP-1912948-B1 ANTIBACTERIAL QUINOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-09-09 EP disclosed
US-7915292-B2 2-{benzyl-[(6-methyl-2-phenyl-quinolin-3-yl)-phenyl-methyl]-amino}-N-(4-methyl-piperazin-1-yl)-acetamide; tuberculosis; antimycobacterial drugs; a tertiary nitrogen atom in the alpha position in the side chain attached to the 3-position of the quinoline nucleus to get fewer enantiomers possible JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed
US-20100204270-A1 Quinoline Derivatives as Antibacterial Agents JANSSEN PHARMACEUTICA N.V. (BE) 2010-08-12 US disclosed
US-20080182855-A1 Antibacterial Quinoline Derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-31 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 MAPT 3963/4885HTT 1585/4885RAB9A 3470/4885
US-20100204270-A1 Quinoline Derivatives as Antibacterial Agents NQO2, NDUFB7, NQO1 MAPT 334/4885HTT 3818/4885RAB9A 988/4885
US-20080182855-A1 Antibacterial Quinoline Derivatives NDUFB5, NQO2, MT-ND5 MAPT 135/4885HTT 2116/4885RAB9A 950/4885
US-20170202795-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY STAT3, STAT1, STAT5A MAPT 4441/4885HTT 3741/4885RAB9A 2823/4885
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MAPT 4163/4885HTT 2860/4885RAB9A 3765/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS MAPT 4477/4885HTT 3147/4885RAB9A 2829/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS MAPT 4477/4885HTT 3147/4885RAB9A 2829/4885
US-20160326125-A1 SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LIPE, LPL MAPT 4306/4885HTT 4627/4885RAB9A 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.